🔴 Veracyte is trading 4.1% down with no clear catalyst

Veracyte is trading 4.1% down at $43.38 on October 12, 2026, with no clear company-specific announcement explaining the intraday drop.

• Recent coverage discussed the stock’s decline following Decipher Prostate data, but that news predates this session and does not establish a direct cause.
• Broader markets were mixed, while the biotech ETF was down about 0.4%.
• Available evidence does not point to a clear market-wide or sector catalyst.